A research team from the University of Cambridge in the UK has recently made a groundbreaking announcement: the world's inaugural DNA vaccine, meticulously designed by artificial intelligence (AI), has successfully completed its first round of human trials. This innovative vaccine is engineered to offer comprehensive, broad-spectrum protection against all currently known variants of human coronaviruses, as well as potential future viruses that might jump from bats to humans, all with a single dose. The trial results have been highly promising, demonstrating not only the vaccine's safety but also its ability to elicit a robust immune response against multiple coronaviruses.
